SCHEMBL6412922

SCHEMBL6412922

COC(=O)c1ccc(/C=N/Nc2nc3nonc3nc2Nc2ccccc2F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.46
KMT2A Q03164 9/20 0.46
MEN1 O00255 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
GAA P10253 5/20 0.46
KDM4E B2RXH2 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
ALDH1A1 P00352 2/20 0.46
BIRC5 O15392 1/20 0.45
HTT P42858 3/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 1/20 0.44
TP53 P04637 1/20 0.43
CDKN1A P38936 1/20 0.43
POLB P06746 3/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6412928 1.00 MAPT (0.46) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL20570809 0.84 MAPT (0.60) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL6721450 0.81 MAPT (0.52) MAPTKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL6412931 0.78 KMT2A (0.42) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL6414365 0.76 GAA (0.55) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL6413566 0.75 BIRC5 (0.48) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL6419602 0.74 MAPT (0.46) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL6419595 0.74 MAPT (0.46) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL13310246 0.74 KMT2A (0.49) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL17240563 0.73 SMN1; SMN2 (0.47) MAPTKMT2AMEN1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445677-B2 Substituted pyrimidyl guanidine derivatives having anticancer activity UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2013-05-21 US disclosed
US-8445677-B2 Substituted pyrimidyl guanidine derivatives having anticancer activity UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2013-05-21 US disclosed
US-8183236-B2 Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-05-22 US disclosed
US-8183236-B2 Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-05-22 US disclosed
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2010-06-24 US disclosed
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2010-06-24 US disclosed
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-02 US disclosed
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-02 US disclosed
WO-2006029850-A1 HYDRAZONE DERIVATIVES AND THEIR USE AS BETA SECRETASE INHIBITORS THE GENETICS COMPANY, INC. (CH) 2006-03-23 WO disclosed
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE ABCG2, NQO2, TOP1 MAPT 4028/4885KMT2A 1733/4885MEN1 1470/4885
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS TYMP, IMPDH1, SAMHD1 MAPT 2174/4885KMT2A 1477/4885MEN1 4601/4885
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885KMT2A 3640/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.